Skip to main content

News Discussions

Trending topics from trusted journalism, transformed into structured debates. Unlike our community discussions, these are automatically curated from breaking news to spark timely, nuanced conversation.

How is this different from Explore?

News Discussions are automatically generated from trending stories in real-time. Explore Discussions shows community-created topics on any subject. Both use the same structured debate format, but News focuses on current affairs.

Our News Sources (156 trusted outlets)

We aggregate stories from these reputable sources to ensure balanced, quality coverage:

Acquired Podcast Africa Confidential Al Jazeera English Al Monitor All-In Podcast AllAfrica Americas Quarterly Andrew Sullivan Anne Applebaum Ars Technica Associated Press Axios BBC News BBC Sport BBC World Service Bloomberg Brookings Institution CSIS Caixin Global Carbon Brief Carnegie Endowment Cato Institute Channel NewsAsia Chartbook Chatham House Christianity Today City Journal Clean Energy Wire CoinDesk Columbia Journalism Review Commentary Magazine Commonweal Cory Doctorow Daily Maverick Daily Wire Decrypt Deutsche Welle Diary of a CEO E&E News ESPN El País América El País English Euractiv Eurostat Ezra Klein Farnam Street Financial Times First Things Foreign Affairs Foreign Policy France24 Francis Fukuyama Freddie deBoer Haaretz Hot Air Huberman Lab IEA IMF Ian Bremmer Institute for Fiscal Studies Institute for Government International Crisis Group Jonathan Rauch Law & Liberty Le Monde English Lex Fridman Podcast MIT Technology Review Mail & Guardian Manhattan Institute Marginal Revolution Matt Taibbi Modern Wisdom National Review Nature News New Statesman Nieman Lab Nikkei Asia Noahpinion Not Boring OECD Office for Budget Responsibility Office for National Statistics Our World in Data Paul Graham Pew Research Center Platformer Politico Politico EU Power Line Poynter ProPublica RAND Corporation Radical with Amol Rajan RealClearPolitics Reason Resolution Foundation Rest of World STAT News Science Magazine Semafor Simon Willison Sixth Tone Sky Sports Slow Boring South China Morning Post Spiegel International Straits Times Stratechery Tablet Magazine TechCrunch The American Conservative The Athletic The Atlantic The Block The Commentary Magazine The Conversation The Critic The Dispatch The Economist The Ezra Klein Show The Federalist The Free Press The Guardian The Independent The Intercept The Lancet The National The New York Times The New Yorker The News Agents The Observer The Pragmatic Engineer The Rest Is Politics The Slow Newscast The Spectator US The Telegraph The Tim Ferriss Show The Times The Verge Time Tortoise Media Triggernometry UK Parliament UN News US Census Bureau UnHerd Vox WHO Wall Street Journal War on the Rocks Washington Examiner Wired World Bank World Economic Forum Yascha Mounk Zeynep Tufekci
Healthcare

How can we improve treatment options for patients with squamous NSCLC based on recent research findings?

We read with interest the results of the HARMONi-6 trial by Zhiwei Chen and colleagues,1 which showed that ivonescimab plus chemotherapy improved progression-free survival versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (NSCLC). However, PD-L1-based subgroup results reveal a critical stratification signal. In patients with PD-L1 tumour proportion score (TPS) of under 50%, dual blockade achieved marked benefit (hazard ratio [HR] 0·63; 95% CI 0·41–0·98), whereas in patients with PD-L1 TPS of 50% or over, the improvement was numerical but not significant (HR 0·71; 0·37–1·33)

Global
Economy

What are the benefits and drawbacks of a president having the power to set tariffs without review?

US President Donald Trump’s tariffs returned to court on Friday, as a three-judge Court of International Trade panel in New York sharply questioned both sides while weighing the legality of a new set of tariffs he imposed in February, shortly after a Supreme Court ruling declared most of his sweeping levies unlawful. While the judges offered few clues on how they might rule on the Section 122 tariffs, the court has previously rejected business challenges seeking to invalidate Section 301 tariffs

Hong Kong
Healthcare

How can modern neuroscience inform public policy to address trauma and fear in communities?

In this Huberman Lab Essentials episode, I explore the neuroscience of fear and trauma and how to effectively process and eliminate traumatic responses. I explain why successful fear treatment requires both extinction of the old fearful response and replacement with a new positive association—not just cognitive reframing. I also explain how the threat reflex activates specific circuits connecting the amygdala, prefrontal cortex, and dopamine systems, and why detailed recounting of traumatic events progressively reduces their physiological impact. Finally, I review evidence-based approaches, including prolonged exposure therapy and cognitive behavioral therapy, discuss how five minutes per day of deliberate stress through cyclic hyperventilation can rewire fear responses, explain the critical role of social connection in activating neural pathways that reduce trauma, and share supplementation options for managing anxiety. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AGZ by AG1: https://drinkagz.com/huberman LMNT: https://drinklmnt.com/huberman Function: https://functionhealth.com/huberman Timestamps (0:00) Introducing Fear & Trauma (0:17) What is Fear? (1:03) Autonomic Arousal: "Alertness" vs. "Calmness" (2:05) Fear vs. Stress & Anxiety (9:20) "The Threat Reflex": Neural Circuits for Fear (20:50) Cognitive (Narrative) Therapies for Fear (26:35) PTSD Treatments: Ketamine, MDMA, Oxytocin (33:11) Deliberate Brief Stress Can Erase Fears & Trauma (35:51) Nutrition, Sleep, & Other General Support Erasing Fear & Trauma (38:18) Recap Disclaimer & Disclosures

Global